|
| Friday, January 18, 2019 |
|
|
Eisai's Notification Regarding Results of Voluntary Retirement Program |
| Eisai Co., Ltd. announced today that the application period for the first round of the voluntary retirement program it announced on October 25, 2018, has ended and hereby discloses the results. more info >> |
|
| Tuesday, January 15, 2019 |
|
|
Eisai's New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States |
| Eisai Co., Ltd. and Purdue Pharma L.P. today announced that a new drug application has been submitted to the U.S. Food and Drug Administration (FDA) for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for the treatment of insomnia, a sleep-wake disorder. more info >> |
|
|
Eisai to Present Results of Post-Hoc Analyses of Lenvima (Lenvatinib) Phase III Reflect Study in Hepatocellular Carcinoma at 2019 Gastrointestinal Cancers Symposium |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting the latest data from post-hoc analyses of a Phase III clinical study (REFLECT/Study 304) on its in-house discovered multiple receptor tyrosine kinase inhibitor lenvatinib mesylate as first-line treatment for unresectable hepatocellular carcinoma (HCC) will be presented during the 2019 Gastrointestinal Cancers Symposium (ASCO-GI) in San Francisco. more info >> |
|
| Friday, January 4, 2019 |
|
|
Eisai's Etak Antimicrobial Spray Alpha Wins Nikkei Business Daily Awards for Superiority at the 2018 Nikkei Superior Products and Services Awards |
| Eisai Co., Ltd. has announced that it received a "Nikkei Business Daily Awards for Superiority" for its Etak Antimicrobial Spray Alpha, which contains long-acting antimicrobial agent Etak, at the 2018 Nikkei Superior Products and Services Awards sponsored by Nikkei Inc. more info >> |
|
|
Eisai's New Drug Application for Perampanel Designated for Priority Review by China National Medical Products Administration |
| Eisai Co., Ltd. announced that its in-house discovered and developed AED perampanel, for which a NDA was submitted for review as an adjunctive treatment for partial onset seizures in epilepsy patients 12 years of age and older in China in October 2018, has been designated for Priority Review by the NMPA due to perampanel's significant clinical benefit compared to existing treatments. more info >> |
|
| Tuesday, December 18, 2018 |
|
|
Eisai: Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3's RNA Splicing Platform |
| Bristol-Myers Squibb Company, Eisai Co., Ltd. and its U.S.-based precision medicine research & development subsidiary H3 Biomedicine, Inc. has announced a multi-year research collaboration focused on evaluating whether novel therapeutics leveraging H3's RNA splicing platform can provide a more powerful response against cancer. more info >> |
|
| Monday, December 17, 2018 |
|
|
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Brazil with Eurofarma |
| Under this agreement, Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for sales in Brazil. more info >> |
|
| Wednesday, December 12, 2018 |
|
|
GARDP, Eisai and Takeda Announce Partnership in the Search for New Antibiotics |
| The Global Antibiotic Research and Development Partnership (GARDP), Eisai Co., Ltd. and Takeda Pharmaceutical Company Limited have signed an agreement for GARDP to access and screen components of Eisai and Takeda's chemical libraries. more info >> |
|
| Thursday, December 6, 2018 |
|
|
Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research |
| Eisai Co., Ltd. and University College London (UCL) announced today that they have commenced preparations for Phase I clinical studies on E2814, the first clinical candidate from their drug discovery collaboration, in Alzheimer's disease patients within fiscal 2018. more info >> |
|
| Thursday, November 29, 2018 |
|
|
Eisai: MOVICOL Launched in Japan |
| MOVICOL is the first polyethylene glycol preparation indicated for treatment of chronic constipation in Japan, available for adults and children 2 years of age and older. more info >> |
|
|
|
